Financials

  • Market Capitalization 250.32 K
  • Employee 142
  • Founded 2001
  • CEO Yaky Yanay
  • Website www.pluri-biotech.com
  • Headquarter Nevada, United States
  • FIGI BBG000DQX509
  • Industry Biotecnologia
Receita total
Lucro líquido
Lucro básico por ação
Dívida total
Fluxo de caixa livre
Caixa e equivalentes de caixa
Índice preço/lucro
-1.39
Índice preço/fluxo de caixa
23.48

Pluri Inc. - Common Stock

Pluri Inc., formerly Pluristem Therapeutics, is an Israeli company engaged in the development of human placental adherent stromal cells for commercial use in disease treatment. According to the company's website, it extracts adult stem cells exclusively from postnatal placentas.

Notícias